<DOC>
	<DOCNO>NCT01969695</DOCNO>
	<brief_summary>This Phase 1 , open-label , multicenter , extension study . Subjects non-Hodgkin 's lymphoma ( NHL ) ( exclude chronic lymphocytic lymphoma [ CLL ] , small lymphocytic lymphoma [ SLL ] , mantle cell lymphoma [ MCL ] ) complete prior ABT-199 study , active assign ABT-199 study complete , may roll extension study . Subjects receive ABT-199 study .</brief_summary>
	<brief_title>An Extension Study ABT-199 Subjects With Advanced Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Subject complete prior ABT199 study ( meet criterion diagnosis NHL eligibility criterion previous study ) investigator believe treatment ABT199 best interest subject . Subject discontinue ABT199 administration complete prior study ( due disease progression , toxicity , withdrawn consent , ) . Subject medical condition opinion investigator place subject unacceptably high risk toxicity . Subject recover â‰¤ Grade 2 clinically significant adverse effect ( ) /toxicity ( y ) previous therapy . Subject diagnose PostTransplant Lymphoproliferative Disease ( PTLD ) , Burkitt 's lymphoma , Burkittlike lymphoma , lymphoblastic lymphoma/leukemia , chronic lymphocytic leukemia ( CLL ) , small lymphocytic lymphoma ( SLL ) , mantle cell lymphoma ( MCL ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>ABT-199</keyword>
	<keyword>Safety</keyword>
	<keyword>Refractory</keyword>
	<keyword>GDC-0199</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Cancer</keyword>
</DOC>